These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Tsuboyama T; Onishi H; Kim T; Akita H; Hori M; Tatsumi M; Nakamoto A; Nagano H; Matsuura N; Wakasa K; Tomoda K Radiology; 2010 Jun; 255(3):824-33. PubMed ID: 20501720 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics. Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Sanada J; Koda W; Minami T; Inoue D; Yoshida K; Yamashita T; Yamashita T; Kaneko S; Takamura H; Ohta T; Ikeda H; Nakanuma Y; Kita R; Gabata T Radiology; 2015 Jun; 275(3):708-17. PubMed ID: 25668519 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131 [TBL] [Abstract][Full Text] [Related]
10. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633 [TBL] [Abstract][Full Text] [Related]
11. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802 [TBL] [Abstract][Full Text] [Related]
12. Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signature. Miura T; Ban D; Tanaka S; Mogushi K; Kudo A; Matsumura S; Mitsunori Y; Ochiai T; Tanaka H; Tanabe M Am J Surg; 2015 Sep; 210(3):561-9. PubMed ID: 26105803 [TBL] [Abstract][Full Text] [Related]
13. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022 [TBL] [Abstract][Full Text] [Related]
14. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. Lee MH; Kim SH; Park MJ; Park CK; Rhim H AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of the peritumoral decreased uptake area of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid in hepatocellular carcinoma. Nishie A; Asayama Y; Ishigami K; Kakihara D; Nakayama T; Ushijima Y; Takayama Y; Shirabe K; Fujita N; Kubo Y; Hirakawa M; Honda H J Gastroenterol Hepatol; 2014 Mar; 29(3):561-7. PubMed ID: 24219648 [TBL] [Abstract][Full Text] [Related]
16. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Jang KM; Kim SH; Kim YK; Choi D Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304 [TBL] [Abstract][Full Text] [Related]
17. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319 [TBL] [Abstract][Full Text] [Related]
18. Peri-tumoral hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced MRI in hepatocellular carcinomas: correlation with peri-tumoral hyperplasia and its pathological features. Yoneda N; Matsui O; Kitao A; Komori T; Kozaka K; Ikeda H; Yoshida K; Inoue D; Minami T; Koda W; Kobayashi S; Gabata T Abdom Radiol (NY); 2018 Aug; 43(8):2103-2112. PubMed ID: 29260280 [TBL] [Abstract][Full Text] [Related]
19. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Yamashita T; Kitao A; Matsui O; Hayashi T; Nio K; Kondo M; Ohno N; Miyati T; Okada H; Yamashita T; Mizukoshi E; Honda M; Nakanuma Y; Takamura H; Ohta T; Nakamoto Y; Yamamoto M; Takayama T; Arii S; Wang X; Kaneko S Hepatology; 2014 Nov; 60(5):1674-85. PubMed ID: 24700365 [TBL] [Abstract][Full Text] [Related]
20. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis. Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]